Övrig

FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

0

0

0 Visningar· 07/10/23

OncLive® On Air
0 Prenumeranter

I

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

Visa mer

0 Kommentarer

Strax

Autospela

Hem

Utforska mer

Hjälp